Document:

Exhibit 10.24

 

***Certain identified information has been omitted from this exhibit
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. Such omitted
information is indicated by brackets (“[...***...]”) in this exhibit. ***

 

MATERIAL TRANSFER AGREEMENT

 

This Material Transfer Agreement (this “Agreement”)
is made and entered into as of January 9, 2021 (the “Effective Date”) between Jasper Therapeutics, Inc.,
a Delaware corporation with a principal place of business at 2200 Bridge Pkwy Suit #102, Redwood City, CA 94065 (“Jasper”),
and Graphite Bio, Inc., a Delaware corporation with a principal place of business at 279 E Grand Ave, Suite 430, South
San Francisco, CA 94080 (“Graphite”). Jasper and Graphite are referred to each as a “Party”
or collectively as the “Parties”, respectively.

 

RECITALS

 

WHEREAS, Jasper has developed
the JSP191 antibody which binds to the CD117 receptor for stem cell factor on blood forming cells (“JSP191”); and

 

WHEREAS, Graphite has developed
the GPH201 investigational drug product, where a functional IL2RG cDNA is precisely integrated at the start site of the endogenous IL2RG
genomic locus in hematopoietic stem and progenitor cells; and

 

WHEREAS, the Parties are interested
in undertaking the Research Plan (attached as Annex III) (the “Research Plan”) to test the hypothesis that
combining JSP191 antibody to clear the humanized NSG mouse model bone marrow niche will allow sufficient engraftment of GPH201 in the
bone marrow at levels that are expected to be therapeutically beneficial (the “Project”) based on the terms and conditions
set forth herein.

 

NOW, THEREFORE, in consideration
of the foregoing and the mutual covenants and premises contained in this Agreement, the receipt and sufficiency of which are hereby expressly
acknowledged, the parties hereto agree as follows:

 

		1.	Supply of Materials.

 

1.1
Promptly following full execution of this Agreement: (i) Jasper shall provide Graphite free of charge with the Jasper Material
(as defined in Annex I) for use in the Project, in such amounts as specified in Annex I and will conduct the work
described in the Research Plan; and (ii) Graphite shall provide Jasper free of charge with the Graphite Material (as defined in Annex II)
for use in the Project, in such amounts as specified in Annex II and will conduct the work described in the Research Plan.
The Jasper Material and Graphite Material are referred to each as “Material”, and collectively, the “Materials”.

 

		2.	Permitted Use of Materials.

 

2.1
Each Party shall remain the sole owner of the Material provided by such Party and hereby grants to the other Party a non-exclusive,
royalty free, fully paid up license to use such Material solely for the purposes of this Agreement. Each Party shall be entitled to use
the other Party’s Material only within the scope of this Agreement and the Project and shall not be entitled to use such Material
for any other purposes. Without limiting the foregoing, neither Party shall be permitted to use the other Party’s Material for any
further research or development activities, outside the Project, or for any commercialization purposes. The Parties shall discuss future
development options for JSP191 as a conditioning regimen for Graphite’s other programs.

 

    

     

    

 

2.2
Neither Party shall: (i) provide or disclose the other Party’s Material to any other third party without the other Party’s
prior written consent, except that the Parties may provide and disclose the other Party’s Material without such consent to the third
parties set forth in Appendix IV, provided such third parties are bound by obligations of confidentiality and non- use on similar
terms to those set out in herein; or (ii) use the other Party’s Material in any other experiments than the experiments described
in the Research Plan and, in particular, neither Party shall reverse-engineer or analyze, or cause and/or permit reverse-engineering or
analysis of the other Party’s Material, whether physically, chemically or biologically. Each Party shall immediately return to the
other Party any unused Material of the providing Party at any time upon the providing Party’s request or, after termination of this
Agreement, without the providing Party’s request.

 

		3.	Allocation of Costs.

 

The Parties shall each be responsible for fifty
percent (50%) of external costs necessary to perform the Research Plan (which costs are expected to be up to two hundred fifty thousand
dollars (US$250,000)). Subject to the Definitive Agreement or other mutual agreement of the Parties, Graphite will be responsible for
all costs of any study to be performed by the Parties other than as set forth in the Research Plan, including all human clinical studies,
in consideration for Jasper’s provision of Jasper Material free of charge for use in such studies.

 

		4.	Exclusive Option.

 

4.1
Jasper hereby grants to Graphite an exclusive option (“Option”) to become Jasper’s sole development partner
for JSP191 in the field of gene therapy for SCID patients with IL2RG deficiency (X-SCID) (the “Field”) during the period
in which Graphite is engaged in the development and commercialization of products for treatment of SCID patients with IL2RG deficiency
(X-SCID), in all cases subject to the terms and conditions of a definitive agreement to be entered into by the Parties after Graphite’s
exercise of the Option (the “Definitive Agreement”). For the avoidance of doubt, this Agreement and the Definitive
Agreement do not and will not limit in any respect the right or ability of Jasper to partner with any third party for the commercialization
of JSP191 for any gene therapies other than for SCID patients with IL2RG deficiency. Further, Graphite acknowledges and agrees that Jasper
has in the past and will continue to undertake research, development, and commercialization activities with respect to allogeneic transplant
in SCID (including SCID IL2RG patients), which activities are not considered competitive with Graphite, and nothing in this Agreement
or the Definitive Agreement will limit in any respect the right or ability of Jasper to develop and commercialize JSP191 for use in connection
with allogeneic transplant in SCID (including SCID IL2RG patients).

 

4.2
Graphite may exercise the Option at any time during the term of this Agreement by providing written notice to Jasper and paying
Jasper an Option exercise fee of [...***...] dollars (US$[...***...]). The Definitive Agreement shall have terms and
conditions mutually acceptable to the Parties and will include a [...***...] dollar (US$[...***...]) milestone payment
from Graphite to Jasper upon the first approval in the United States of [...***...], and a [...***...] dollar (US$[...***...])
milestone payment from Graphite to Jasper upon the first approval outside of the United States of [...***...]. The Definitive
Agreement shall be signed no later than [...***...] after the date Graphite has exercised the Option. If Graphite elects not
to exercise the Option or the Parties are unable to agree upon the terms of the Definitive Agreement despite good-faith negotiations during
such [...***...] period then Jasper may grant to any other party an exclusive partnership for JSP191 in the Field. Jasper will
promptly refund the Option exercise fee to Graphite if the parties are unable to agree upon the terms of the Definitive Agreement despite
good-faith negotiations during such [...***...] period. Confidential Information.

 

    2

     

    

 

		5.	Confidentiality; Press Release.

 

5.1
Confidential Information means any and all data, information, scientific or technical information relating to Jasper Material,
the Graphite Material, procedures, formulae, data, improvements, developments, manufacturing processes, trade secrets and know-how and
other commercially valuable information of whatever description and in whatever form (whether written or oral, visible or invisible)
owned or controlled by either Party and made available by such Party (the “Disclosing Party”) to the other Party (or
its agents or contractors) (the “Receiving Party”). For clarity, the Jasper Material and information relating thereto
is and shall be deemed the Confidential Information of Jasper, while the Graphite Material and all information relating thereto is and
shall be deemed the Confidential Information of Graphite. The Receiving Party will: (i) keep confidential all of the Disclosing Party’s
Confidential Information; (ii) not use the Disclosing Party’s Confidential Information except for the purpose of this Agreement;
and (iii) not disclose, without the Disclosing Party’s prior written consent, the Disclosing Party’s Confidential Information
to any person except to those of its employees, officers, directors, consultants, agents and advisors who have a need to know it, and
who shall be bound by obligations of confidentiality and non-use on similar terms to those set out in this clause. The Receiving Party
will use all reasonable endeavors to ensure that those employees, officers, directors, consultants, agents and advisors will comply with
their obligations of confidentiality.

 

5.2
Nothing in this Agreement prohibits the Receiving Party disclosing or using Confidential Information, that, as can be shown by
written records or equivalent evidence of the Receiving Party: (i) is or becomes generally available in the public domain, otherwise
as a result of any non-compliance with the terms of this Agreement; or (ii) was known to the Receiving Party prior to disclosure
hereunder; or (iii) is disclosed, revealed or otherwise made available to the Receiving Party by a third party that is under no obligation
of non-disclosure to the Disclosing Party.

 

5.3
The Receiving Party shall also be entitled to disclose Confidential Information if and to the extent such Confidential Information
is required to be disclosed under applicable law or by court order; provided, however, that the Receiving Party shall furnish the Disclosing
Party with as much prior written notice of such disclosure as reasonably practicable, so as to permit the Disclosing Party, in its sole
discretion, to take appropriate action in order to prevent the Disclosing Party’s Confidential Information from passing into the
public domain or becoming generally available to the public. The Receiving Party shall take necessary steps to limit the scope of Confidential
Information to the required minimum.

 

5.4
Any non-compliance with the confidentiality obligations set out in this Section 5 shall be considered a material breach
of this Agreement.

 

5.5
Press Releases and Disclosure. Neither Party may issue any press release or make any public announcements regarding this
Agreement or any matter covered by this Agreement, without the prior written consent of the other Party. The Parties shall agree on an
initial press release regarding this Agreement in the form set forth in Annex IV to be issued at such time(s) as are set forth
in Annex IV.

 

		6.	Properties of the Materials.

 

Each Party acknowledges that the other Party’s
Material is experimental in nature, may have hazardous properties and is supplied by the other Party on an “as is” basis.
Neither Party gives any warranty and each Party expressly excludes any responsibility for the suitability of such Party’s Material
for use according to the Research Plan. Each Party understands and agrees that the other Party’s Material is to be handled and used
with caution, and that such Material is not to be used for testing in or treatment of humans. EACH PARTY’S MATERIAL IS PROVIDED
WITH NO WARRANTIES OF ANY KIND, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THEY ARE FREE FROM
THE RIGHTFUL CLAIM OF ANY THIRD PARTY, BY WAY OF INFRINGEMENT OR THE LIKE.

 

    3

     

    

 

		7.	Reports.

 

Each Party shall undertake in a timely and professional
manner, in accordance with industry best practices and all applicable laws and regulations, all studies and analyses designated for performance
by such Party set forth in the Research Plan and will furnish to the other Party a written report detailing the uses made of the Materials
and a description of the results including all data and relevant procedures made or obtained by such Party during the course of the Project
(the “Reports”). The Reports will be deemed the Confidential Information of both Parties, provided that either Party
shall have the right to share the results of the Project and the Reports in a blinded form with third parties under obligations of confidentiality,
to the extent reasonably necessary or desirable in connection with any regulatory filings or approvals sought by either Party, or in connection
with any financing, investment, acquisition, or other strategic transaction involving such Party.

 

		8.	Intellectual Property Rights / Results.

 

8.1
Any intellectual property rights, including, but not limited to patent rights, technologies, know-how and trade secrets (“Intellectual
Property Rights”) owned by a Party or licensed by a third party to a Party as of the Effective Date (the “Background
IP”) shall in relation to the other Party, remain the sole property of the Party that owned or was licensed to use such Background
IP. For the avoidance of doubt, the Parties agree that the Jasper Material shall be deemed Jasper Background IP and the Graphite Material
shall be deemed Graphite Background IP.

 

8.2
The Parties agree that Jasper shall exclusively own any and all Intellectual Property Rights developed by either Party (either
independently or jointly) that relate exclusively or primarily to the Jasper Background IP (the “Jasper Improvements”).
Graphite hereby irrevocably and unconditionally assigns to Jasper all right, title, and interest Graphite may have in or to any and all
Jasper Improvements.

 

8.3
The Parties agree that Graphite shall exclusively own any and all Intellectual Property Rights developed by either Party (either
independently or jointly) that relate exclusively or primarily to the Graphite Background IP (the “Graphite Improvements”).
Jasper hereby irrevocably and unconditionally assigns to Graphite all right, title, and interest Jasper may have in or to any and all
Graphite Improvements.

 

8.4
Any Intellectual Property Rights developed under this Agreement that are neither Jasper Improvements nor Graphite Improvements,
and that are developed exclusively by one Party shall be sole property of such Party.

 

8.5
Any Intellectual Property Rights jointly developed by the Parties that are not Jasper Improvements or Graphite Improvements shall
be jointly owned by both Parties, without a duty of accounting to the other Party.

 

8.6
Graphite hereby grants to Jasper a non-exclusive, royalty-free license during the term of this Agreement to use the Graphite Background
IP and the Graphite Improvements to the extent reasonably necessary for Jasper to undertake its obligations in furtherance of the Project.

 

8.7
Jasper hereby grants to Graphite a non-exclusive, royalty-free license during the term of this Agreement to use the Jasper Background
IP and Jasper Improvements to the extent reasonably necessary for Graphite to undertake its obligations in furtherance of the Project.

 

8.8
With respect to Intellectual Property Rights developed in furtherance of the Project and exclusively owned by Jasper (including
Jasper Improvements), and that are relevant to the research, development, manufacture, use, sale, import, export or other exploitation
of Graphite’s products (whether for clinical or commercial activity), Jasper hereby grants to Graphite a worldwide, perpetual, non-exclusive,
royalty-free license to such Intellectual Property Rights for Graphite to use and exploit such Intellectual Property Rights without restriction
in connection with Graphite’s products and services (including Graphite’s GPH201and clinical applications thereof in general),
but excluding any use in connection with JSP191 or any other product or service that would be competitive with JSP191.

 

8.9
With respect to Intellectual Property Rights developed in furtherance of the Project and exclusively owned by Graphite (including
Graphite Improvements), and that are relevant to the research, development, manufacture, use, sale, import, export or other exploitation
of JSP191 (whether for clinical or commercial activity), Graphite hereby grants Jasper a worldwide, perpetual, non-exclusive, royalty-free
license to such Intellectual Property Rights for Jasper to use and exploit such Intellectual Property Rights without restriction in connection
with Jasper’s products and services (including JSP191), but excluding any use in connection with Graphite’s GPH201 or any
other product or service that would be competitive with Graphite’s GPH201.

 

8.10
There are no implied rights or licenses granted under this Agreement, and except as expressly provided herein, each Party shall
retain all right, title, and interest in and to all of such Party’s respective Intellectual Property Rights. Without limiting the
foregoing, nothing in this Agreement shall act as any assignment or transfer of the Background IP of either Party.

 

    4

     

    

 

		9.	Term and Termination.

 

This Agreement is effective as of the Effective
Date, and shall expire upon completion of the Project, which shall include delivery of a final report in accordance with the Research
Plan. Either Party may terminate this Agreement at its convenience with thirty (30) days’ prior written notice to the other
Party, or immediately for any material breach by the other Party of the provisions of this Agreement that remains uncured for fifteen
(15) days following written notice of such breach to the other Party. Each Party’s confidentiality obligations and non- disclosure
restrictions, as well as the licenses set forth in Sections 8.8 and 8.9, shall survive expiration or termination
of this Agreement.

 

Upon termination or expiration of this Agreement:
(i) Graphite shall return the remaining Jasper Material and destroy all Jasper Confidential Information in its possession or control,
and shall also deliver to Jasper a statement signed by an authorized representative of Graphite certifying that all such Jasper Material
and Confidential Information have been so delivered or destroyed; and (ii) Jasper shall return the remaining Graphite Material and
destroy all Graphite Confidential Information in its possession or control, and shall also deliver to Graphite a statement signed by an
authorized representative of Jasper certifying that all such Graphite Material and Confidential Information have been so delivered or
destroyed.

 

		10.	Representations and Warranties.

 

Each Party represents and warrants to the other
Party that: (i) such Party has full right, power, and authority to enter into and perform this Agreement without the consent of any
third party, including the right to grant all licenses granted by such Party in this Agreement; (ii) such Party has the appropriately
qualified and experienced staff and the necessary equipment, experience, means and techniques in order for its activities hereunder to
be performed in accordance with the terms and conditions of this Agreement; (iii) such Party’s obligations under the Research
Plan shall be performed in a timely, professional and workmanlike manner, consistent with generally accepted industry standards, and in
compliance with applicable laws and regulations; and (iv) none of such Party’s employees in connection with this Agreement
have been debarred or disqualified by any regulatory authority or under any applicable laws or regulations, and such Party will not use
in any capacity in connection with this Agreement the services of any individual debarred or disqualified by any regulatory authority
or under any applicable laws or regulations.

 

		11.	Indemnification.

 

Each Party hereby agrees to defend, indemnify
and hold the other Party, its directors, officers, employees and agents, harmless from and against any third party loss, claim, damage
or liability of any kind which may arise from the use, handling or storage of the other Party’s Materials by or through the handling
or storing Party, except to the extent such loss, claim, damage, or liability is caused by the gross negligence or willful misconduct
of the other Party. Each Party hereby agrees to defend, indemnify and hold the other Party, its directors, officers, employees and agents,
harmless from and against any third party loss, claim, damage or liability of any kind which may arise from the gross negligence or willful
misconduct of such Party in connection with this Agreement.

 

		12.	Limitation of Liability.

 

EXCEPT ARISING OUT OF A PARTY’S INDEMNIFICATION
OBLIGATIONS OR BREACH OF CONFIDENTIALITY OBLIGATIONS HEREUNDER, OR FOR A PARTY’S WILLFUL MISCONDUCT OR GROSS NEGLIGENCE, TO THE
FULLEST EXTENT PERMITTED BY LAW, NEITHER PARTY SHALL BE LIABLE TO THE OTHER UNDER THIS AGREEMENT FOR ANY INJURY TO OR LOSS OF GOODWILL,
REPUTATION, BUSINESS, PRODUCTION, REVENUES, PROFITS, ANTICIPATED PROFITS, CONTRACTS OR OPPORTUNITIES (REGARDLESS OF HOW THESE ARE CLASSIFIED
AS DAMAGES), OR FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY, SPECIAL, PUNITIVE OR ENHANCED DAMAGES WHETHER ARISING OUT OF BREACH
OF CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, PRODUCT LIABILITY OR OTHERWISE, REGARDLESS OF WHETHER SUCH LOSS OR DAMAGE
WAS FORESEEABLE OR SUCH PARTY HAD BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSS OR DAMAGE, AND NOTWITHSTANDING THE FAILURE OF ANY AGREED
OR OTHER REMEDY OF ITS ESSENTIAL PURPOSE.

 

    5

     

    

 

		13.	Assignment.

 

Neither Party may assign any rights or duties
under this Agreement to any other party without the prior written consent of the other Party, provided, however, that either Party may
assign this Agreement to a third party in connection with a sale of all or substantially all of the business or assets of such Party related
to this Agreement.

 

		14.	Applicable Law / Place of Jurisdiction.

 

The form, execution, validity, construction and
effect of this Agreement shall be determined by the laws of New York, New York, regardless of the choice of law principles of that or
any other jurisdiction. The rights and obligations of the Parties under this Agreement shall not be governed by the 1980 U.N. Convention
on Contracts for the International Sale of Goods, to the extent applicable.

 

Exclusive place of jurisdiction for all disputes
arising from or in connection with this Agreement is New York, New York.

 

		15.	Entire Agreement; Amendments.

 

This Agreement constitutes the entire understanding
of the Parties and supersedes any previous Agreements between the Parties (whether written or oral) relating to the subject matter. All
modifications or amendments to this Agreement shall be done in writing executed by both Parties.

 

		16.	Force Majeure.

 

If either Party hereto is prevented from carrying
out its obligations under this Agreement by events beyond its reasonable control, acts of God or government, natural disasters, including
earthquakes or storms, fire, political strife, terrorism, failure or delay of transportation, then such Party’s performance of its
obligations hereunder shall be excused during the period of such events and for a reasonable period of recovery thereafter, and the time
for performance of such obligations shall be automatically extended for a period of time equal to the duration of such events; provided,
however, that the Party claiming force majeure shall promptly notify the other Party of the existence of such force majeure, shall use
commercially reasonable efforts to avoid or remedy such force majeure and shall continue performance hereunder promptly whenever such
force majeure is avoided or remedied.

 

		17.	Severability.

 

If any provision of this Agreement shall be determined
to be invalid or unenforceable, the validity of the other provisions shall remain unaffected. The Parties shall attempt in good faith
to negotiate and replace the respective provision by another provision which is valid and enforceable and which represents the purpose
of the original provision as closely as possible. This shall apply accordingly to any unintended gaps in the Agreement.

 

[Signature Page Follows]

 

    6

     

    

 

IN WITNESS WHEREOF, the undersigned have duly
executed and delivered this Agreement as of the date first written above.

 

	Jasper Therapeutics, Inc.	 	Graphite Bio, Inc.
	 	 	 
	By:	/s/ William Lis	 	By:	/s/ Joshua Lehrer
	Name: 	William Lis	 	Name: 	Joshua Lehrer
	
    Title:

    
	 Executive Chairman & CEO

    

    
	 	
    Title:

    

    
	CEO

    

     

    

	Date:	January 9, 2021	 	Date:	January 9, 2021

 

    7

     

    

 

Annex I

[...***...]

 

    8

     

    

 

Annex II

[...***...]

 

    9

     

    

 

Annex III

[...***...]

 

    10

     

    

 

Annex IV

Press Release

 

		

 

Jasper Therapeutics and Graphite Bio Announce
Collaboration to Evaluate JSP191 as Conditioning Regimen for Novel Gene Replacement Therapy in Patients with XSCID

 

REDWOOD CITY, Calif. January XX, 2021 -- Jasper
Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, and Graphite Bio, Inc. a next-generation
gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced a
research and clinical collaboration agreement to evaluate JSP191, Jasper’s first-in-class anti-CD117 monoclonal antibody, as a targeted,
non-toxic conditioning regimen for Graphite Bio’s investigational GPH201 gene replacement therapy for severe combined immune deficiency
(SCID) in patients with IL2RG deficiency, known as x-linked SCID (XSCID).

 

XSCID is a severe, inherited disorder of the immune
system with symptoms often presenting in early infancy, including persistent infections and failure to thrive. Without treatment, XSCID
is typically fatal to patients in the first two years of life.

 

Graphite Bio is focused on the development of
potentially curative therapies for patients suffering from serious diseases, using its targeted gene integration platform to harness the
natural cellular process of homology directed repair (HDR) in order to efficiently repair genetic defects at their source, deliver
genetic cargo with precision and engineer new cellular effector functions. Jasper Therapeutics’ JSP191 is a first-in-class humanized
monoclonal antibody that depletes hematopoietic stem cells from bone marrow and acts as a conditioning agent in patients prior to receiving
a hematopoietic stem cell transplant. JSP191 is currently being evaluated in multiple trials as a stem cell depleting conditioning agent,
including a Phase 1/2 trial to achieve donor stem cell engraftment in SCID patients undergoing hematopoietic cell transplant and
a separate Phase 1/2 trail in AML/MDS patients undergoing hematopoietic cell transplant.

 

“This collaboration with Jasper demonstrates
our shared commitment to pioneering novel therapeutic approaches with the potential to significantly improve the treatment experiences
of individuals with devastating conditions who stand to benefit from gene replacement therapies, initially for patients with XSCID,”
said Josh Lehrer, M.Phil., M.D., chief executive officer at Graphite Bio. “GPH201 harnesses our targeted gene integration platform
to precisely target the defective gene that causes XSCID and replacing it with a normal copy. We are impressed by the initial positive
clinical results demonstrated by JSP191 when used as a conditioning regimen, and look forward to collaborating with the Jasper team to
explore how our novel technologies can be brought to more patients with XSCID and other indications.”

 

“Our collaboration with Graphite Bio is
an exciting opportunity to further advance the field of curative gene correction, by combining a targeted gene integration platform with
our first-in-class targeted CD117 antibody, JSP191, that has already demonstrated preliminary clinical efficacy and safety as a conditioning
agent in XSCID patients and those with blood cancers undergoing allogeneic hematopoietic stem cell transplant,” said Bill Lis executive
chairman and CEO, Jasper Therapeutics.

 

    11

     

    

 

Graphite Bio and Jasper will collaborate on research,
and potentially a clinical study, evaluating JSP191 as a conditioning agent for GPH201. Each company will retain commercial rights to
their respective technologies.

 

About JSP191

 

JSP191 (formerly AMG 191) is a first-in-class
humanized monoclonal antibody in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow. JSP191
binds to human CD117, a receptor for stem cell factor (SCF) that is expressed on the surface of hematopoietic stem and progenitor
cells. The interaction of SCF and CD117 is required for stem cells to survive. JSP191 blocks SCF from binding to CD117 and disrupts critical
survival signals, causing the stem cells to undergo cell death and creating an empty space in the bone marrow for donor or gene-corrected
transplanted stem cells to engraft.

 

Preclinical studies have shown that JSP191 as
a single agent safely depletes normal and diseased hematopoietic stem cells, including in animal models of SCID, myelodysplastic syndromes
(MDS) and sickle cell disease (SCD). Treatment with JSP191 creates the space needed for transplanted normal donor or gene-corrected
hematopoietic stem cells to successfully engraft in the host bone marrow. To date, JSP191 has been evaluated in more than 90 healthy
volunteers and patients.

 

JSP191 is currently being evaluated in two separate
clinical studies in hematopoeitc cell transplant. The first clinical study is evaluating JSP191 as a sole conditioning agent in a Phase 1/2
dose- escalation and expansion trial to achieve donor stem cell engraftment in patients undergoing hematopoietic cell transplant for
severe combined immunodeficiency (SCID), which is potentially curable only by this type of treatment. JSP191 is also being evaluated
in combination with another conditioning regimen in a Phase 1 study in patients with MDS or acute myeloid leukemia (AML) who
are receiving hematopoietic cell transplant. For more information about the design of these clinical trials, visit www.clinicaltrials.gov
(NCT02963064 and NCT04429191).

 

Additional studies are planned to advance JSP191
as a conditioning agent for patients with other rare and ultra-rare monogenic disorders and autoimmune diseases.

 

About GPH201

 

GPH201 is a first-in-human investigational hematopoietic
stem cell treatment that will be evaluated as a potentially curative therapy for patients suffering from XSCID. GPH201 is generated using
Graphite Bio’s precise and efficient targeted gene integration platform technology to directly replace the defective IL2RG gene,
maintain normal IL2RG regulation and expression, and ultimately lead to the production of fully functional adaptive immune cells.

 

About Jasper Therapeutics

 

Jasper Therapeutics is a biotechnology company
focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The company’s lead compound,
JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing
a hematopoietic cell transplant. This first-in-class conditioning antibody is designed to enable safer and more effective curative hematopoietic
cell transplants and gene therapies. For more information, please visit us at jaspertherapeutics.com.

 

    12

     

    

 

About Graphite Bio, Inc.

 

Graphite Bio is a next-generation gene editing
company focused on the development of potentially curative therapies for patients suffering from serious diseases. The company’s
targeted geneintegration platform harnesses the natural cellular process of homology directed repair (HDR) to efficiently repair
genetic defects at their source, deliver genetic cargo with precision and engineer new cellular effector functions. Graphite Bio is leveraging
its differentiated platform, initially focused on ex vivo engineering of hematopoietic stem cells, to advance a portfolio of transformative
treatments with potential for saving and dramatically improving patients’ lives. The company was co-founded by academic pioneers
in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, MD, and Matthew Porteus, MD, PhD, and is backed by
Versant Ventures and Samsara BioCapital. For more information, please visit graphitebio.com.

 

# # #

 

Contacts:

 

Jasper Therapeutics

Lily Eng

W2O

206-661-8627

leng@w2ogroup.com

 

Jeet Mahal

Jasper Therapeutics

650-549-1403

jmahal@jaspertherapeutics.com

 

Graphite Bio

Christy Curran

615.414.8668

media@graphitebio.com

 

 

13Exhibit
10.30

 

***Certain
identified information has been omitted from this exhibit because it is both (i) not material and (ii) would likely cause competitive
harm to the Registrant if publicly disclosed. Such omitted information is indicated by brackets (“[...***...]”) in this exhibit.
***

 

IND
SPONSOR: NIAID

 

CLINICAL
TRIAL AGREEMENT

 

For
Clinical Trials Conducted at the National Institutes of Health Clinical Center

 

BETWEEN

 

THE
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

 

(NIAID)

 

AND

 

Jasper
Therapeutics, Inc.

 

Protocol
# 16-I-0032

 

High
Dose Peripheral Blood Stem Cell Transplantation with Post Transplant Cyclophosphamide for Patients with Chronic Granulomatous Disease

 

Version 1.0

 

    	 	 	 

     

    

 

	NIAID Intramural Clinical Trial Agreement (Clinical Center)	NIAID Protocol # 16-I-0032
	Jasper Therapeutics NIAID	 

 

The
National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), which is part
of the United States Government Department of Health and Human Services (HHS), as represented by the Division of Intramural Research
(DIR), and Jasper Therapeutics, Inc. (“Company”), located at 2200 Bridge Parkway, Ste. 102, Redwood City,
CA 94065 (individually referred to as the “Party” and collectively referred to as the “Parties”) have agreed
to cooperate in the conduct of a clinical trial at the NIH Clinical Center, in Bethesda, Maryland, designated as Protocol No. 16-1-0032
for JSP191, the title of which is “High Dose Peripheral Blood Stem Cell Transplantation with Post Transplant
Cyclophosphamide for Patients with Chronic Granulomatous Disease.”

 

This
Agreement sets forth the terms and conditions under which this Protocol will be conducted and the Clinical Trial will be managed.

 

The
Company and the NIAID agree as follows:

 

		1.	DEFINITIONS

 

The
terms listed in this Section have the meanings indicated throughout this Agreement. To the extent a definition of a term as provided
in this Section is inconsistent with a corresponding definition in the applicable sections of either the United States Code (U.S.C.)
or the Code of Federal Regulations (C.F.R.), the definition in the U.S.C. or C.F.R. will control.

 

“Adverse
Event” (AE) means any untoward medical occurrence in a Human Subject to whom the Test Article has been administered
or the definition as otherwise stated in the Protocol. An Adverse Event does not necessarily have a causal relationship with the Test
Article, that is, it can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally
associated with the use of the Test Article, whether or not it is related to it. Adverse Event is further defined in ICH E6 section 1.2
and 21 C.F.R 312.32.

 

“Affiliates”
means, with respect to the Company:

 

		(i)	any
                                            legal entity of which the securities or other ownership interests representing fifty per
                                            cent (50%) or more of the equity or fifty per cent (50%) or more of the ordinary
                                            voting power or fifty per cent (50%) or more of the general partnership interest are,
                                            at the time such determination is being made, owned, controlled or held, directly or indirectly,
                                            by such legal entity, or

 

		(ii)	any
                                            legal entity which, at the time such determination is being made, is controlling or under
                                            common control with, such legal entity.

 

As
used in this definition, the term “control”, whether used as a norm or verb, refers to the possession, directly or indirectly,
of the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting
securities, by contract or otherwise.

 

“Agreement”
means this Clinical Trial Agreement or “CTA,” all executed amendments and supplements to this Agreement, and all schedules
to this Agreement.

 

“Case
Report Form” (CRF) means the data collection form(s) to be completed for each Human Subject participating in the
Clinical Trial.

 

    	 	 	Page 2 of 21

     

    

 

	NIAID Intramural Clinical Trial Agreement (Clinical Center)	NIAID Protocol # 16-I-0032
	Jasper Therapeutics NIAID	 

 

“Certificate
of Confidentiality” (CoC) means a certificate issued by NIH pursuant to Section 301(d) of the Public Health
Service Act (42 U.S.C. 241(d)), that protects the privacy of Human Subjects enrolled in the Protocol. With limited exceptions defined
in 42 U.S.C. 241(d), the CoC protects from disclosure names or any information, documents, or biospecimens containing ISI collected
under the Protocol conducted under this CTA.

 

“Clinical
Research Site” means the NIH Clinical Center, their contractors, and Investigators at Bethesda, Maryland, USA where the Clinical
Trial will be conducted in strict accordance with the Protocol.

 

“Clinical
Study Report” in accordance with ICH E6 Section 1.13, is a written description of a Clinical Trial in which the clinical
and statistical description, presentations, and analyses are fully integrated into a single report. The Clinical Study Report contains
information on results including reactogenicity, adverse events, immunogenicity, and other clinical or laboratory observations made with
respect to the intervention employed in conducting the trial. A detailed description of the contents of a Clinical Trial Report is found
in ICH E3 “Structure and Content of Clinical Study Reports.”

 

“Clinical
Trial” is defined by the NIH as a research study in which one or more human subjects are prospectively assigned to one or more
interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical
or behavioral outcomes. In this Agreement, Clinical Trial means the Clinical Trial for the Protocol.

 

“Completion
of the Clinical Trial” means when all data analyses under the Protocol have been performed and the Clinical Study Report has
been submitted to the FDA, thus completing the Clinical Trial.

 

“Confidential
Information” means confidential scientific, proprietary, business, or financial information provided that Confidential Information
does not include:

 

		(a)	information
                                            that is within the public domain prior to the time of the disclosure by the disclosing Party
                                            to the receiving Party or thereafter becomes within the public domain other than as a result
                                            of disclosure by the receiving Party or any of its representatives in violation of this Agreement;

 

		(b)	information
                                            that was, on or before the date of disclosure, in the possession of the receiving Party without
                                            an obligation of confidentiality;

 

		(c)	information
                                            that is acquired by the receiving Party from a third party not under an obligation of confidentiality;

 

		(d)	information
                                            that is hereafter independently developed by the receiving Party without reference to the
                                            Confidential Information received from the disclosing Party;

 

		(e)	information
                                            that the disclosing Party expressly authorizes the receiving Party to disclose;

 

		(f)	information
                                            that is reasonably required by scientific standards for publication of the results of the
                                            Clinical Trial (including Clinical Trial methods and/or data) or any information that is
                                            necessary for other researchers to verify the results of the Clinical Trial; or

 

		(g)	information
                                            that relates to potential hazards or cautionary warnings associated with the production,
                                            handling, or use of the Test Article.

 

    	 	 	Page 3 of 21

     

    

 

	NIAID Intramural Clinical Trial Agreement (Clinical Center)	NIAID Protocol # 16-I-0032
	Jasper Therapeutics NIAID	 

 

“Data
and Safety Monitoring Board” (DSMB) is an independent group of experts that advises the NIAID and the Investigators.
The primary responsibilities of the DSMB are to: (i) to periodically review and evaluate the accumulated data of the Clinical Trial
for participant safety, Clinical Trial conduct and progress, and, when appropriate, efficacy; and (ii) to make recommendations to
NIAID concerning the continuation, modification, or termination of the Clinical Trial.

 

“Data
Coordination Center” (DCC) means an organization funded by the NIAID that receives, reviews, and performs data
management tasks on the individual Human Subject Case Report Forms completed for this Clinical Trial. The Data Coordination Center for
this Clinical Trial will be the LHD intramural staff using CRIS, CRIMSON, and Btris as well as REDCAP where appropriate.

 

“Distributor”
is the NIAID contractor who will be distributing the Test Article to the Clinical Research Site. The Distributor for this Clinical Trial
is [Insert Name].

 

“Effective
Date” means the date of the last signature of the authorized representatives of the Parties executing this Agreement.

 

“Food
and Drug Administration” (FDA) means the U.S. Food and Drug Administration.

 

“Government”
means the federal government of the United States of America.

 

“Genome-Wide
Association Study” (GWAS) means any study of genetic variation across the entire human genome that is designed
to identify genetic associations with observable traits (such as blood pressure or weight) or the presence or absence of a disease or
condition.

 

“Human
Subject” as defined in 45 CFR 46 means a living individual about whom an Investigator conducting research obtains
(l)data through intervention or interaction with the individual or (2) Identifiable Private Information.

 

“Identifiable
Private Information” (IPI) means private information about a Human Subject from which the identity of the Human
Subject is or may readily be ascertained. Regulations defining and governing this information include 45 C.F.R. Part 46 and 21
C.F.R. Part 50.

 

“Identifiable,
Sensitive Information” (ISI) means, in accordance with the definition of 42 U.S.C. 241(d)(4), information
that is about an individual and that is gathered or used during the course of research as described in 42 U.S.C. 241(d)(1)(A) through
which an individual is identified, or that includes IPI, or for which there is at least a very small risk, as determined by current scientific
practices or statistical methods, that some combination of the information, a request for the information, and other available data sources
could be used to deduce the identity of an individual.

 

“Independent
Safety Monitor” (ISM) is a physician or other expert who is independent of a study and readily available to review
and recommend actions on adverse events and other safety issues.

 

“Informed
Consent Form” means a signed and documented form in which each Human Subject voluntarily consents or confirms his or her willingness
to participate in a particular clinical trial after having been informed of all aspects of the trial that are relevant to the subject’s
decision to participate. The informed consent form satisfies the requirements of ICH E6, 45 C.F.R. Part 46 and 21 C.F.R. Part 50.

 

    	 	 	Page 4 of 21

     

    

 

	NIAID Intramural Clinical Trial Agreement (Clinical Center)	NIAID Protocol # 16-I-0032
	Jasper Therapeutics NIAID	 

 

“Institutional
Review Board” (IRB) means, in accordance with 45 C.F.R. Part 46, Protection of Human Subjects (Revised
November 13, 2001) and 21 C.F.R. Part 56, Subpart C: IRB Functions and Operations (as amended June 18, 1991), and
other applicable regulations, an independent body comprising medical, scientific, and nonscientific members, whose responsibility is
to ensure the protection of the rights, safety, and well-being of the Human Subjects involved in a Clinical Trial. It may also be referred
to as an Independent Ethics Committee in accordance with ICH E6, Section 1.27.

 

“The
International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use” (ICH).
ICH refers to one or all of the following requirements used throughout this Agreement:

 

		(a)	ICH
                                            E2F: “Development Safety Update Report”, including the latest finalized revision,
                                            if any.

 

		(b)	ICH
                                            E3: “Structure and Content of Clinical Study Reports”, including the latest
                                            finalized revision, if any.

 

		(c)	ICH
                                            E6: “Good Clinical Practice: Consolidated Guidance”, published in the Federal
                                            register (62 Federal Register 25692 (1997)), including the latest finalized revision.
                                            Also referred to as “FDA Good Clinical Practice Guidelines”.

 

		(d)	ICH
                                            Q7: “Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients”
                                            published in the Federal register (66 Federal Register 49028-9 (2001)), including the
                                            latest finalized revision, if any.

 

“Invention”
means any invention or discovery that is or may be patentable or otherwise protected under 35 U.S.C., or any novel variety of plant
which is or may be protectable under the Plant Variety Protection Act, 7 U.S.C. §§ 2321 et seq.

 

“Investigational
New Drug Application” (IND) is filed in accordance with 21 C.F.R. Part 312 under which clinical investigation
of a Test Article (an experimental drug or biologic) is performed in Human Subjects in the United States or intended to support
a United States licensing action.

 

“Investigator”
means, in accordance with 21 C.F.R. Part 312.3, an individual who actually conducts a clinical trial, that is, who directs
the administration or dispensation of Test Article to a subject, and who assumes responsibility for studying Human Subjects, for recording
and ensuring the integrity of research data, and for protecting the welfare and safety of Human Subjects. In this Agreement, “Investigator(s)”
means the individual(s) identified as responsible for the conduct of the Clinical Trial at the Clinical Research Site.

 

“Investigator
Brochure” (IB) means, in accordance with the definition in 21 C.F.R. Part 312.23(a)(5), a document containing
information about the Test Article, including animal screening, preclinical toxicology, and detailed pharmaceutical data, including a
description of possible risks and side effects to be anticipated on the basis of prior experience with the Test Article or related drugs,
and precautions, such as additional monitoring, to be taken as part of the investigational use of the Test Article.

 

    	 	 	Page 5 of 21

     

    

 

	NIAID Intramural Clinical Trial Agreement (Clinical Center)	NIAID Protocol # 16-I-0032
	Jasper Therapeutics NIAID	 

 

“Office
of Human Research Protections” (OHRP) means the HHS office that oversees protection of human subjects from research
risks under 45 C.F.R. Part 46 (the Common Rule).

 

“Party”
means an entity entering into this Agreement, referred to individually as the “Party” and collectively as the “Parties”.

 

“Patent”
means any issued United States patent, any international counterpart and any corresponding grant by a non-U.S. government in place
of a patent.

 

“Protocol”
means the formal, detailed description of the Clinical Trial to be performed as provided in Protocol 16-1-0032 for
JSP191 the title of which is “High Dose Peripheral Blood Stem Cell Transplantation with Post Transplant Cyclophosphamide
for Patients with Chronic Granulomatous Disease.” A Protocol describes the objective(s), design, methodology, statistical considerations,
and organization of a clinical trial. For the purposes of this Clinical Trial, the term Protocol includes any and all associated documents,
including informed consent forms, to be provided to Human Subjects and potential participants in the Clinical Trial. This Clinical Trial
Agreement will be governed by the most recent version of the Protocol, and should this Agreement be executed prior to complete finalization
of the Protocol, the last-dated version thereof will be considered to be incorporated by reference in place of any prior versions. In
the event that there is a conflict between the terms of the Protocol and the terms of the Agreement, the terms of this Agreement will
govern.

 

“Protocol
Team” means the team, under the direction of NIAID, responsible for the development and management of the Protocol, evaluation
of data, proposal of amendments, and all issues related to the Protocol or aspects of Protocol development and modification. The Protocol
Team will include the representatives from the Company, if they wish to participate, the principal Investigators, representatives from
the NIAID, and the persons involved with statistical and data analysis for the Clinical Trial. Participation on the Protocol Team will
be as agreed by the Parties and will take into account any special requirements of the Protocol design.

 

Monitoring
will be performed by the NIAID OCRPRO.

 

“Serious
Adverse Event” or “Serious Suspected Adverse Reaction” means the definitions as stated in the Protocol.

 

“Sponsor”
means, in accordance with the definition in 21 C.F.R. Part 312.3, an organization or individual who assumes legal responsibility
for supervising or overseeing the Clinical Trial with Test Article, and is sometimes referred to as the “IND holder”.
The Sponsor for the Protocol is NIAID.

 

“Sponsor
Medical Monitor” or “SMM” is a Sponsor appointed physician with relevant expertise whose primary responsibility
is to provide safety monitoring in a timely fashion. This is accomplished by review of adverse events, per protocol specification, with
follow-up through resolution. The SMM evaluates individual and cumulative participant data when making recommendations regarding the
safe continuation of the Clinical Trial.

 

“Suspected
Adverse Reaction” means the definition as stated in the Protocol.

 

“Test
Article” means, in accordance with 21 C.F.R. Part 50.3(j), any drug (including a biological product), medical device,
food additive, color additive, electronic product, material or any other article subject to regulation under the Federal Food, Drug,
and Cosmetic Act, 21 U.S.C. §§ 301, et seq., Pub. L.No.75-717, 52 Stat. 1040 (1938), as amended. In this Agreement,
JSP191 is/are collectively are referred to as the “Test Article”.

 

    	 	 	Page 6 of 21

     

    

 

	NIAID Intramural Clinical Trial Agreement (Clinical Center)	NIAID Protocol # 16-I-0032
	Jasper Therapeutics NIAID	 

 

“Investigational
Drug Delivery Errors” means the definition as stated in the Protocol.

 

“Unexpected/Unanticipated
Problem” or “Unexpected/Unanticipated Suspected Problem” means the definitions as stated in the Protocol.

 

		2.	CLINICAL
                                            RESEARCH SITE AND INVESTIGATORS

 

		2.1	The
                                            NIAID will not knowingly utilize:

 

		2.1.1	Any
                                            organization performing services in connection with this Clinical Trial that has been:

 

		(i)	Debarred
                                            under the provisions of the Generic Drug Enforcement Act of 1992, 21 U.S.C. §
                                            335a(a) and (b); or

 

		(ii)	Suspended
                                            by the Office for Human Research Protections (OHRP) as a clinical research site under 45
                                            C.F.R. Part 46; or

 

		2.1.2	Any
                                            person convicted of a felony under federal law for conduct:

 

		(i)	Relating
                                            to the development or approval, including, but not limited to, the process for development
                                            or approval, of any drug, product, medical device, New Drug Application (NDA), Pre-Market
                                            Application (PMA), 510(k), or IND, or similar application; or

 

		(ii)	Otherwise
                                            relating to the regulation of any drug product or medical device under the FD&C Act;
                                            or

 

		2.1.3	Any
                                            person performing services in connection with this Clinical Trial that has been disqualified
                                            as a clinical investigator under 21 C.F.R. Part 312.70; or

 

		2.1.4	Any
                                            Investigator who is not qualified by training and experience as an appropriate expert to
                                            conduct the Clinical Trial, as required under 21 C.F.R. Part 312.53.

 

		2.2	If
                                            either Party becomes aware that any organization or person involved in the Clinical Trial
                                            is debarred, threatened with debarment, disqualified, threatened with disqualification, or
                                            suspended, that Party will notify the other Party immediately.

 

		2.3	The
                                            NIAID will conduct the Clinical Trial in accordance with good clinical practice, including
                                            as defined by the ICH and comply with all applicable U.S. and foreign government, state,
                                            and local laws, regulations, and guidelines.

 

		2.4	The
                                            Company agrees that this Protocol will be conducted only at the Clinical Research Site. However,
                                            the Company can conduct, at its own expense and under its own IND, additional clinical trials
                                            with the Test Article, at non-NIAID-funded sites. The Company agrees to inform the NIAID
                                            in writing of any other clinical trials it may support for the use of the Test Article that
                                            would compete with this Clinical Trial for the same Human Subject population. NIAID acknowledges
                                            that the Test Article constitutes proprietary technology of the Company, and as such, Company
                                            may develop protocols that have similar elements in part to the Protocol.

 

    	 	 	Page 7 of 21

     

    

 

	NIAID Intramural Clinical Trial Agreement (Clinical Center)	NIAID Protocol # 16-I-0032
	Jasper Therapeutics NIAID	 

 

		3.	INVESTIGATIONAL
                                            NEW DRUG APPLICATION SPONSORSHIP

 

		3.1	IND.
                                            The NIAID will submit an IND covering the Protocol to the FDA. The IND will satisfy all of
                                            the requirements of the FDA. The Company will provide a letter granting the FDA permission
                                            to cross-reference the Company’s pertinent Drug Master File (DMF), New Drug Application
                                            (NDA), Biologics License Application (BLA), and/or INDs in support of the NIAID for the limited
                                            purpose of the IND, and in return, the NIAID will also provide a letter to the Company, if
                                            requested, granting the FDA permission to cross-reference the IND filed by the NIAID for
                                            this Clinical Trial.

 

		3.2	Protocol
                                            Monitoring. The NIAID will be responsible for Clinical Research Site monitoring and quality
                                            assurance of all data in accordance with the clinical monitoring plan. Monitoring will be
                                            done in compliance with FDA Good Clinical Practice Guidelines (ICH) (E6). The NIAID will
                                            communicate any clinically significant findings from clinical monitors to the Company in
                                            a timely manner.

 

		3.3	Safety
                                            Reporting

 

		3.3.1	The
                                            NIAID will collect safety reports according to the procedure outlined in the Protocol. The
                                            NIAID will assume responsibility for the reporting of safety reports to the FDA and will
                                            provide copies of the reports to the Company.

 

		(i)	NIAID
                                            will provide to the Company, all Serious Adverse Events within [...***...]
                                            of discovery. The Company will provide analysis of similar events for expedited safety cases.

 

For
any safety report that meets all of the following criteria of (i) Serious (ii) Unexpected and (iii) Suspected Adverse
Reaction, NIAID will provide to the Company, a completed copy of the safety report at the time the report is submitted to the FDA. NIAID
will provide follow up information to Company at the time the follow up safety report is submitted to FDA. The reporting will be completed
in the timeframes consistent with 21 CFR 312.32.

 

		(ii)	The
                                            NIAID will report all other Serious and non-serious Adverse Events to the FDA and to the
                                            Company on a timely basis consistent with 21 C.F.R. Part 312.33 and the Protocol.

 

		3.3.2	As
                                            the manufacturer, the Company will, in a timely manner consistent with FDA requirements and
                                            during the term of this Clinical Trial, provide the NIAID with any material information it
                                            now has or may obtain in the future regarding the safety and/or the toxicity of Test Article.
                                            The NIAID will promptly transmit that information to all Investigators.

 

		3.3.3	NIAID,
                                            as the sponsor of the clinical trial, can either provide FDA with a DSUR (Development Safety
                                            Update Report) and state certain information is not available to them or provide the information
                                            to the Company in the required timeframe so that it can be included in the Company’s
                                            DSUR.

 

    	 	 	Page 8 of 21

     

    

 

	NIAID Intramural Clinical Trial Agreement (Clinical Center)	NIAID Protocol # 16-I-0032
	Jasper Therapeutics NIAID	 

 

		3.4	Safety
                                            Monitoring. In accordance with NIH guidelines the Company and the NIAID agree that the
                                            following type(s) of safety monitoring is (are) necessary and appropriate for this Clinical
                                            Trial:

 

		(a)	Independent
                                            Safety Monitor (ISM). If deemed necessary, the NIAID will appoint an ISM for
                                            the Clinical Trial; and

 

		(b)	Data
                                            and Safety Monitoring Board (DSMB). A DSMB will continue to monitor the Clinical
                                            Trial, and the NIAID will notify the Company in advance of any DSMB review. The Company will
                                            receive the any identified safety concerns identified by the DSMB within [...***...]
                                            of receiving that information. Prior to the Completion of the Clinical Trial, data and reports
                                            distributed for DSMB review will be used only for the purposes of the DSMB meeting and will
                                            be held in confidence by the DSMB.

 

		4.	FDA
                                            MEETINGS/COMMUNICATIONS

 

		4.1	With
                                            respect to any discussions with the FDA involving data obtained from this Clinical Trial
                                            under NIAID’s IND, the NIAID, in consultation with the Company, will take the initiative
                                            in arranging meetings or conference calls with the FDA. Formal meetings with the FDA concerning
                                            the Clinical Trial design and/or data will be discussed and agreed upon in advance by the
                                            Company and the NIAID. The Company will have the right to participate in all formal meetings
                                            with the FDA. The Company agrees not to contact the FDA independent of the NIAID concerning
                                            this Clinical Trial. However, the Company may contact the FDA on separate product-related
                                            issues.

 

		4.2	The
                                            Company will promptly notify NIAID of any FDA correspondence related to the Protocol that
                                            is received by the Company, or its Affiliates; any FDA enforcement actions directed toward
                                            the Company or its Affiliates related to the Test Article, including but not limited to:
                                            warning letters, seizures, recalls, injunctions/consent decrees, rejection of regulatory
                                            submissions or withdrawal of approval for a Test Article, criminal investigations, and proceedings
                                            to debar the Company or its Affiliates or individuals employed under a contract to the Company
                                            and/or its Affiliates.

 

		4.3	The
                                            Company will also promptly notify NIAID of any action taken by the FDA regarding manufacturing
                                            of the Test Article that would impact the safety of Human Subjects in the Clinical Trial.

 

		5.	SUPPLY,
                                            DISTRIBUTION, AND USE OF TEST ARTICLE

 

		5.1	Supply.

 

		5.1.1	The
                                            Company will only supply the Test Article for the number of patients described in the clinical
                                            protocol to the NIAID [...***...] and will use commercially reasonable efforts
                                            to supply the Test Article in quantities and conditions sufficient to complete the Protocol
                                            and on a schedule mutually agreed upon by the Parties to ensure a sufficient supply of unexpired
                                            Test Article.

 

		5.1.2	The
                                            Company will be responsible for labeling the Test Article used in the Clinical Trial.

 

		5.2	Distribution.

 

		5.2.1	The
                                            Company will ship the Test Article to the Clinical Research Site as mutually agreed by the
                                            Parties. The Company will provide specific storage and/or shipping instructions for the Test
                                            Article to the NIAID, who will be responsible for adhering to them, as mutually agreed by
                                            the Parties. The Company warrants that any packaging for hazardous material provided by the
                                            Company meets Department of Transportation regulatory requirements for use at the Clinical
                                            Research Site.

 

    	 	 	Page 9 of 21

     

    

 

	NIAID Intramural Clinical Trial Agreement (Clinical Center)	NIAID Protocol # 16-I-0032
	Jasper Therapeutics NIAID	 

 

		5.2.2	The
                                            Test Article must be received by the Clinical Research Site in usable condition and accompanied
                                            by Material Safety Data Sheet (MSDS), specific storage and shipping instructions, stability
                                            and/or expiration dating information and the finally signed and dated Certificate of Analysis
                                            (COA) for each lot of Test Article sent. If the Company performs ongoing stability testing
                                            for each lot of Test Article sent, then the Company will also provide updated retest or expiration
                                            dates for those respective lots to NIAID in a timely manner.

 

		5.2.3	If
                                            there is evidence that the Test Article that arrived at the Distributor or Clinical Research
                                            Site has not been maintained according to the defined shipping instructions or there is evidence
                                            of damage to the Test Article container or container closure system, NIAID will contact the
                                            Company to inform them of the condition of the received Test Article and to determine together
                                            with the Company whether the Test Article is usable or if it must be replaced. During the
                                            course of the Clinical Trial, the same process will be used whenever there is evidence that
                                            the Test Article has not been maintained according to the Company’s recommended storage
                                            conditions. If the Test Article must be replaced, the Company will replace it at [...***...]
                                            to NIAID.

 

		5.3	Use.

 

		5.3.1	The
                                            NIAID will neither transfer the Test Article to parties other than the Distributor or the
                                            Clinical Research Site nor will the NIAID chemically modify, replicate, make derivatives
                                            of, or reverse engineer the Test Article unless required by the Protocol or mutually agreed
                                            in writing by the Parties.

 

		5.3.2	The
                                            NIAID will request that the Investigators:

 

		(i)	use
                                            the Test Article only in accordance with the Protocol and for no other purpose;

 

		(ii)	not
                                            transfer the Test Article to any parties except the Company; and

 

		(iii)	not
                                            chemically modify, replicate, make derivatives of, or reverse engineer the Test Article unless
                                            required by the Protocol or as mutually agreed to, in writing, by the Parties.

 

		5.4	Investigator
                                            Brochure. The Company will provide a current Investigator Brochure for all applicable
                                            components of the Test Article, and any later revisions and addenda to the Investigator Brochure
                                            for the Test Article to NIAID, as mutually agreed by the Parties, and NIAID shall keep such
                                            components and other aforementioned materials in confidence in accordance with Section 11 (Confidential Information) of this Agreement.

 

		5.5	Disposition
                                            of Unused Test Article. The NIAID will require the Clinical Research Site to destroy
                                            any unused or expired Test Article upon completion of the Protocol.

 

		5.6	Warranty.
                                            The Company represents and warrants that the Test Article supplied shall be manufactured
                                            and released according to the principles of current Good Manufacturing Practice and when
                                            administered in accordance with Protocol it is suitable for human use.

 

		5.7	Source.
                                            In the event the Company elects to terminate its development of Test Article for reasons
                                            other than safety or IRB approval withdrawal, without the transfer of its development efforts
                                            and obligations under this Agreement to another party acceptable to the NIAID within [...***...]
                                            of discontinuation, then the Company will provide the NIAID with Test Article for all then-enrolled
                                            Human Subjects sufficient to complete the Clinical Trial in the manner described in the Protocol,
                                            but only to the maximum number of Human Subjects as identified in the Protocol at the time
                                            of Company’s notice of termination of its development of the Test Article.

 

    	 	 	Page 10 of 21

     

    

 

	NIAID Intramural Clinical Trial Agreement (Clinical Center)	NIAID Protocol # 16-I-0032
	Jasper Therapeutics NIAID	 

 

		5.8	Termination
                                            of Development. The Company hereby grants to the NIAID a nonexclusive, nontransferable,
                                            irrevocable, paid-up license to practice or have practiced for or on behalf of the United
                                            States any invention which the Company has a right to license which the Company may have
                                            or obtain on Test Article, its manufacture, or on the process for use of Test Article, throughout
                                            the world, solely for medical research purposes related to Chronic Granulomatous Disease.
                                            This license will only become effective in the event the Company terminates its development
                                            of Test Article for reasons other than safety or IRB approval withdrawal, without the transfer
                                            of its development efforts to another party within [...***...] of termination,
                                            and the NIAID elects to continue the development of Test Article. This provision will become
                                            null and void upon FDA approval of the Test Article indications and marketing of the Test
                                            Article by the Company.

 

		6.	PROTOCOL
                                            DEVELOPMENT

 

		6.1	The
                                            Parties agree that enrollment in the Clinical Trial will not start until the version of the
                                            Protocol to be used has been reviewed in advance by the Protocol Team; approved (stipulations
                                            met/resolved) by the relevant IRB(s) and the NIAID in writing; and submitted to the FDA,
                                            the thirty (30) calendar day wait period has been satisfied and any FDA clinical hold
                                            issues have been responded to satisfactorily. The Protocol is a product of NIAID and will
                                            be deemed NIAID Confidential Information, as defined in Section 11 (Confidential
                                            Information) of this Agreement.

 

The
Parties agree that any alteration in or amendment to the Protocol must be accepted by the Protocol Team, and approved in writing by the
relevant IRB(s) and the NIAID and submitted to the FDA, if appropriate, prior to such alteration or amendment becoming effective. The
Company will have the right to review any amendments or alterations to the Protocol and NIAID will consider such comments in good faith
in finalizing such amendments or alterations.

 

		6.2	The
                                            NIAID, through its contractors, will be responsible for performing the randomization. [...***...]
                                            will determine who will have access to the randomization codes.

 

		7.	CASE
                                            REPORT FORM DEVELOPMENT

 

The
NIAID or its designee will be responsible for the development and subsequent revisions, if any, of the Case Report Forms with appropriate
review and comment by the Protocol Team.

 

		8.	HUMAN
                                            SUBJECTS PROTECTION

 

		8.1	The
                                            NIAID and the Company recognize the principles of respect for persons, beneficence (including
                                            minimization of harms and maximization of benefits), and justice as stated in the Belmont
                                            Report and will apply these principles in all research covered under this Agreement. The
                                            informed consent of each Human Subject participating in the Clinical Trial at the Clinical
                                            Research Site will be obtained prospectively using an IRB approved informed consent process.
                                            The informed consent document may be reviewed in advance by the Company and approved by the
                                            NIAID (which will consider in good faith any comments provided by the Company) and all appropriate
                                            Institutional Review Board (IRB).

 

    	 	 	Page 11 of 21

     

    

 

	NIAID Intramural Clinical Trial Agreement (Clinical Center)	NIAID Protocol # 16-I-0032
	Jasper Therapeutics NIAID	 

 

		8.2	The
                                            NIAID and the Company acknowledge and accept their responsibilities for protecting the rights
                                            and welfare of human research subjects set forth in 45 C.F.R. Part 46, Protection
                                            of Human Subjects (Revised November 13, 2001) and in a Certificate of Confidentiality
                                            issued by NIH in accordance with 42 U.S.C 241(d) of the Public Health Service Act.

 

Therefore:

 

		8.2.1	Any
                                            ISI that Company receives from NIH is covered by a CoC and therefore all copies of ISI are
                                            immune from the legal process, and will not, without the consent of the Human Subject, be
                                            admissible as evidence or used for any purpose in any action, suit, or other judicial, legislative,
                                            or administrative proceeding.

 

		8.2.2	The
                                            NIAID and the Company will maintain the confidentiality of ISI of Human Subjects collected
                                            under the Clinical Trial and protect the privacy of each of the individual Human Subjects
                                            in the Clinical Trial unless disclosure is required by law (e.g., as required by the Federal
                                            Food, Drug, and Cosmetic Act, or state laws requiring the reporting of communicable diseases
                                            to State and local health departments), excluding instances of disclosure in any Federal,
                                            State, or local civil, criminal, administrative, legislative, or other proceeding. Prior
                                            to making any permitted disclosures, Company will ensure that any recipient of ISI protected
                                            by a CoC is aware of its confidential nature and the requirement to comply with the CoC.

 

		8.2.3	The
                                            NIAID and the Company may inspect, but not copy, Human Subjects’ medical records that
                                            might also include information not directly connected to this Clinical Trial. However, the
                                            NIAID and the Company agree that this information will remain confidential and will not be
                                            used for any purpose other than confirmation of Clinical Trial data.

 

		8.2.4	The
                                            NIAID and the Company agree that neither Party will, nor will they allow the Clinical Research
                                            Sites to, include ISI that could lead to identification of individual Human Subjects in any
                                            release of data, reports or publications related to the Clinical Trial. The NIAID will require
                                            that the Investigators not include ISI that could lead to identification of individual Human
                                            Subjects in any release of data, reports or publications related to the Clinical Trial.

 

		8.2.5	The
                                            NIAID and the Company agree that neither Party will, nor will they allow the Clinical Research
                                            Site to, use ISI about Human Subjects for any purpose not stated in the Protocol without
                                            the consent of the other Party and local site IRB approval. The NIAID will require that the
                                            Investigators not use IPI for any purpose not stated in the Protocol and informed consent
                                            document without the written consent of both Parties and appropriate IRB approval.

 

		8.2.6	The
                                            NIAID and the Company agree to comply with the determinations of all IRBs overseeing this
                                            research.

 

		8.2.7	Human
                                            Subject specimens and data provided, included but not limited to demographic, safety laboratory,
                                            safety data and drug exposure data, to the Company during and after the Clinical Trial will
                                            be coded. Unequivocally, neither IPI nor the key linking coded data to Human Subjects will
                                            be released to the Company.

 

    	 	 	Page 12 of 21

     

    

 

	NIAID Intramural Clinical Trial Agreement (Clinical Center)	NIAID Protocol # 16-I-0032
	Jasper Therapeutics NIAID	 

 

		9.	DATA
                                            ANALYSIS AND MANAGEMENT; CLINICAL SPECIMENS AND ISOLATES

 

		9.1	NIAID
                                            will be responsible for the data and scientific reporting of all results/data obtained from
                                            the Clinical Trial at the Clinical Research Site and the provision of applicable safety data
                                            and reports to Company.

 

		9.2	The
                                            NIAID and/or the DCC will have responsibility for the data management: collection, entry,
                                            and quality control edits (with implied verifications and documentation) and analysis of
                                            data obtained from the Clinical Trial in accordance with the Protocol.

 

		9.3	All
                                            data obtained from the Clinical Trial will be in the custody of the NIAID. However, other
                                            than the Company, its contractors and its designees, NIAID will not allow a third party to
                                            review or use the data obtained from the Clinical Trial for purposes of seeking regulatory
                                            approval unless the third party provides NIAID with written permission from the Company.
                                            NIAID agrees that the Company, its affiliates, its contractors and its designees may review
                                            and use the data obtained from the Clinical Trial for any legitimate business or regulatory
                                            purposes, including for purposes of seeking regulatory approval of the Test Article, with
                                            written notice to the NIAID. For avoidance of doubt, Company may provide any information
                                            regarding the Clinical Trial to governmental organizations including, but not limited to,
                                            the FDA, and the Securities and Exchange Commission (SEC) for all legitimate public
                                            health, regulatory, or business purposes, with written notice to the NIAID.

 

		9.4	Upon
                                            completion of the data analyses, the NIAID will authorize transfer to the Company a copy
                                            of the complete data analysis set in a machine-readable format to be determined jointly by
                                            the Parties. If the Company requires that the data be provided to it in any customized format(s),
                                            the Company will [...***...] associated with the customized data format(s). When
                                            applicable, compressed raw and intermediate genomics and/or other -omics data will be provided
                                            in industry/scientific community accepted data formats (e.g. FASTQ and/or BAM format for
                                            RNA-Sequence transcriptomics studies) at the time of data generation or transfer. Light-weight
                                            derived data such as gene expression values per sample will be provided in SAS format.

 

		9.5	The
                                            NIAID is responsible for sending a final Clinical Study Report to the Company and the FDA
                                            as applicable, according to specified content, within a reasonable time after the dataset
                                            is locked, provided that the Company should have an opportunity to review for safety information
                                            and provide feedback to NIAID on the final Clinical Study Report for up to [...***...].

 

		9.6	Subject
                                            to the right of the NIAID and the Investigators to publish the data from this Clinical Trial
                                            as set forth in Section 10 (Publications and Press Releases) of this Agreement,
                                            the Company has the right to utilize the data reports in its possession and all data obtained
                                            from this Clinical Trial for all legitimate business or regulatory purposes. The NIAID and/or
                                            the Company may provide any information regarding the Clinical Trial to governmental organizations
                                            including, but not limited to, the FDA, and the Securities and Exchange Commission (SEC) for
                                            all legitimate public health, regulatory or business purposes. Except for information related
                                            to regulatory or safety issues or under emergency circumstances where it is not practicable
                                            to do so and to the extent permitted by law, the NIAID will not release information regarding
                                            the Clinical Trial to governmental organizations provided that the Company should have an
                                            opportunity to review and provide feedback regarding safety information to NIAID on the publication
                                            for up to [...***...].

 

		9.7	For
                                            applicable clinical trials, NIAID will post applicable primary and/or secondary endpoint
                                            results within [...***...] of the last visit for primary and/or secondary
                                            end point evaluations. Therefore, any data that will be provided by the Company for primary
                                            or secondary outcomes (i.e. immunogenicity analysis) will be provided to NIAID no later than [...***...]
                                            after the last visit of the last patient evaluated for the primary endpoint.

 

    	 	 	Page 13 of 21

     

    

 

	NIAID Intramural Clinical Trial Agreement (Clinical Center)	NIAID Protocol # 16-I-0032
	Jasper Therapeutics NIAID	 

 

		9.8	Clinical
                                            Specimens for Use in Protocol. All clinical specimens and isolates collected by the Investigators,
                                            or their staff, under this Clinical Trial will be and remain in the custody of NIAID. However,
                                            NIAID will provide Company with clinical specimens and isolates for analysis as stated in
                                            the Protocol. Company agrees to share with NIAID results derived from the analysis of clinical
                                            specimens and isolates.

 

		9.9	During
                                            the Clinical Trial, the NIAID will provide the Company with aliquots of clinical specimens
                                            as needed for Protocol-related purposes only as requested by NIAID. However, nothing in this
                                            Agreement will be interpreted to transfer ownership of such clinical specimens to the Company.

 

		9.10	Clinical
                                            Specimens for Use in Future Research. At the NIAID’s request, only when available and
                                            as permitted by the Informed Consent Form, provide the Company with some aliquots of clinical
                                            specimens, identified only by Clinical Trial subject number and accompanied by related encoded
                                            data for future studies. As stated in Section 8 (Human Subjects Protection) of
                                            this Agreement, the NIAID will provide to the Company only encoded data and encoded samples
                                            and will not provide the link between the code and the Human Subjects. However, nothing in
                                            this Agreement will be interpreted to transfer ownership of such samples to the Company.

 

		9.11	Upon
                                            completion of the studies involving clinical specimens or upon the termination of this Agreement,
                                            whichever comes first, any unused clinical specimens and data derived from Human Subjects
                                            in the Company’s possession will be destroyed unless NIAID gives Company directions
                                            for disposing of the clinical specimens and data by another means.

 

		10.	PUBLICATIONS
                                            and PRESS RELEASES

 

		10.1	Any
                                            publications based on the results of the Clinical Trial and originating from NIAID will conform
                                            to NIH publication policies. Unless requested otherwise by the Company, the NIAID will acknowledge
                                            the Company as the source of the Test Article in any NIAID publication resulting from the
                                            Clinical Trial.

 

		10.2	Recognizing
                                            that employees of either Party may play an important role in the design, analysis, and interpretation
                                            of the findings of the Clinical Trial, each Party will include appropriate individuals from
                                            the other Party in the authorship of publications resulting from the Clinical Trial, in accordance
                                            with the International Committee of Medical Journal Editors authorship criteria.

 

Each
Party will provide the other Party with a copy of any abstract, or manuscript prior to submission for publication with sufficient time
(i.e., for abstracts: at most [...***...]; for manuscripts: at most [...***...]) for review and comment. Each Party
agrees that, following the receiving Party’s review of the abstract or manuscript for the maximum periods of time specified above,
if no comment is received by the submitting Party, the submitting Party will be free to publish, present or use any Clinical Trial data.
The receiving Party will maintain the proposed publication or public disclosure of the submitting Party as Confidential Information until
publication or public disclosure by the submitting Party.

 

		10.3	If
                                            the Company requests additional time to file a patent application related to the publication:
                                            The publication or other disclosure may be delayed for up to [...***...] for publications
                                            and [...***...] for abstracts, upon written request by either Party as necessary
                                            to preserve U.S. or foreign patent or other intellectual property rights.

 

    	 	 	Page 14 of 21

     

    

 

	NIAID Intramural Clinical Trial Agreement (Clinical Center)	NIAID Protocol # 16-I-0032
	Jasper Therapeutics NIAID	 

 

		10.4	Each
                                            Party will provide a copy of any proposed press release to the other Party for review and
                                            comment at least [...***...] in advance of proposed publication. Each Party agrees
                                            that, following the receiving Party’s review of the proposed press release for the
                                            maximum periods of time specified above, if no comment is received by the submitting Party,
                                            the submitting Party will be free to publish the press release.

 

		11.	CONFIDENTIAL
                                            INFORMATION

 

		11.1	Either
                                            Party may disclose or receive Confidential Information under the terms and conditions of
                                            this Agreement. Each receiving Party will limit its disclosure and use of the disclosing
                                            Party’s Confidential Information to the amount necessary to conduct the Clinical Trial,
                                            and will place a confidentiality notice on all the Confidential Information. The disclosing
                                            Party will reduce confidential non-written communications to writing within [...***...]
                                            of first disclosure. Each Party receiving Confidential Information agrees that any information
                                            so designated will be maintained as Confidential Information in accordance with this Agreement
                                            and used by it only for the purposes of the Clinical Trial. Any Party may object to the designation
                                            of information as Confidential by the other Party.

 

		11.2	Unless
                                            expressly provided otherwise, neither Party will disclose, copy, reproduce or otherwise make
                                            the disclosing Party’s Confidential Information available to any other person or entity
                                            without the consent of the disclosing Party unless required by a court or administrative
                                            body of competent jurisdiction, the Freedom of Information Act (FOIA), 5 U.S.C. § 552,
                                            45 C.F.R. Part 5, or other applicable laws and/or regulations to disclose the Confidential
                                            Information, except that the NIAID may disclose the Company’s Confidential Information
                                            to the Investigators and other parties, as required for the conduct of the Clinical Trial
                                            for purposes of the Clinical Trial. The NIAID will request such Investigators and such other
                                            parties receiving the Company’s Confidential Information to maintain the confidentiality
                                            of Confidential Information consistent with the terms of this Agreement.

 

		11.3	Each
                                            Party will use the same level of care it uses with its own Confidential Information, but
                                            no less than a reasonable level of care, in maintaining the confidentiality of the other
                                            Party’s Confidential Information. While the NIAID will endeavor to control the distribution
                                            of the Protocol document itself, the Company acknowledges that some Government documents
                                            are available (with abstracts) to the public under the Freedom of Information Act. In addition,
                                            NIAID requires the posting of information on the ClinicalTrials.gov registry of clinical
                                            studies, available through the NIH Website, consistent with the Food and Drug Administration
                                            Amendments Act of 2007, 121 STAT. 823.

 

		11.4	Consistent
                                            with the NIH policy for sharing data obtained in NIH supported or conducted GWAS, NIAID is
                                            required to submit GWAS data to a central NIH database (database of Genotypes and Phenotypes
                                            (dbGaP)) in accordance with NIH policy, where it may be accessed by Investigators. All data
                                            submitted is coded and de-identified.

 

		11.5	Each
                                            Party agrees that the receiving Party is not liable for the disclosure of Confidential Information
                                            which, after notice to and consultation with the disclosing Party, the receiving Party determines
                                            may not be lawfully withheld, provided the disclosing Party has been given an opportunity
                                            to seek a court order to enjoin from disclosure.

 

		11.6	Each
                                            Party’s obligation to maintain the confidentiality of Confidential Information will
                                            expire at the earlier of the date when the information is no longer Confidential Information
                                            as defined above or [...***...] after the expiration or termination date of this
                                            Agreement. Either Party may request an extension to this term when necessary to protect Confidential
                                            Information relating to [...***...]. This term does NOT apply to ISI, for which
                                            the obligation to maintain confidentiality will extend indefinitely.

 

    	 	 	Page 15 of 21

     

    

 

	NIAID Intramural Clinical Trial Agreement (Clinical Center)	NIAID Protocol # 16-I-0032
	Jasper Therapeutics NIAID	 

 

		12.	INTELLECTUAL
                                            PROPERTY

 

		12.1	Ownership
                                            of any Invention conceived as a consequence of conducting the Clinical Trial and involving
                                            the Test Article, will be determined under U.S. laws pertaining to intellectual property
                                            created in the course of federally funded research. Neither Party acquires by virtue of this
                                            Agreement any right, title, nor interest in or to any issued Patents or pending patent applications
                                            owned or controlled by the other Party. Nothing in this Agreement will be construed as granting
                                            any license or obligation to license any intellectual property owned by the Company to the
                                            NIAID with respect to the Test Article other than the limited right to use the Test Article
                                            for the performance of the Protocol in accordance with the terms of this Agreement.

 

		12.2	NIAID
                                            Intellectual Property.

 

		12.2.1	The
                                            Government will retain title to any Patent, pending patent applications or other intellectual
                                            property rights in Inventions conceived solely by NIAID employees in the course of the clinical
                                            research.

 

		12.2.2	The
                                            NIAID agrees to notify the Company of any NIAID sole or joint Invention arising during the
                                            clinical research and to disclose it to the Company under an appropriate confidentiality
                                            agreement. The Company may apply for nonexclusive or exclusive license rights to any such
                                            patentable Invention made by NIAID employees that might arise during the clinical research
                                            and the NIH will consider the Company’s application for a nonexclusive or exclusive
                                            license consistent with 37 C.F.R. Part 404. The NIAID agrees that if the Parties
                                            enter into a Clinical Cooperative Research and Development Agreement (Clinical CRADA) that
                                            relates to the subject matter of this Agreement it will include terms to be negotiated then
                                            that provide to the Company (i) a non-exclusive, royalty-free, internal-use research
                                            license and (ii) a first and exclusive option for Company to negotiate for a royalty-bearing
                                            exclusive license (or, at Company’s election, non-exclusive license) to any sole or
                                            joint Invention for commercial use, in all cases subject to and consistent with 37 C.F.R.
                                            Part 404.

 

		12.3	Company
                                            Intellectual Property. The Company will retain title to any Patents, pending patent applications,
                                            or other intellectual property rights in Inventions conceived by its employees during the
                                            course of the clinical research.

 

		12.4	Joint
                                            NIAID-Company Intellectual Property. The NIAID and the Company will have joint intellectual
                                            property rights in Inventions conceived jointly by their employees during the course of the
                                            clinical research. Company may receive a non-exclusive or exclusive license to the NIAID
                                            rights in such Inventions in accordance with the 37 CFR 404 and Section 12.2.2.

 

		13.	FORCE
                                            MAJEURE

 

Neither
Party will be liable for any unforeseeable event beyond its reasonable control not caused by the fault or negligence of such Party, which
causes such Party to be unable to perform its obligations under this Agreement, and which it has been unable to overcome by the exercise
of due diligence. In the event of the occurrence of such a force majeure event, the Party unable to perform will promptly notify the
other Party. It will further use its best efforts to resume performance as quickly as possible and will suspend performance only for
such period of time as is necessary as a result of the force majeure event.

 

    	 	 	Page 16 of 21

     

    

 

	NIAID Intramural Clinical Trial Agreement (Clinical Center)	NIAID Protocol # 16-I-0032
	Jasper Therapeutics NIAID	 

 

		14.	LIABILITY,
                                            INDEMNIFICATION, INSURANCE, & RESEARCH RELATED INJURY

 

		14.1	Liability.
                                            In view of the Anti-Deficiency Act, 31 U.S.C § 1341, NIAID cannot agree to indemnify
                                            the Company for its losses. Each Party will be liable for the losses, claims, damages, or
                                            liabilities that it incurs as a result of its activities under this Agreement except that
                                            the NIAID, as an agency of the Government, assumes liability only to the extent provided
                                            under the Federal Tort Claims Act, 28 U.S.C. Ch. 171.

 

		14.2	Indemnification.
                                            Subject to Term 14.5, the Company will defend, indemnify and hold harmless NIAID, and
                                            its grantees and their respective employees (“Indemnitee(s)”) from any
                                            and all liabilities, damages, losses, claims, action, suits and expenses, including attorneys’
                                            fees and court costs (collectively “Claims”) to the extent caused by the
                                            administration or use of the Test Article in the Clinical Trial. The Company’s control
                                            over the defense and settlement of any claim against NIAID will be subject to the consent
                                            of NIAID and the Department of Justice, and such consent may not be unreasonably withheld.
                                            The Indemnitee(s) will at all times have the right to fully participate in the defense of
                                            any Claim at their own expense and for their own account, subject to the foregoing sentence.
                                            Company’s obligation to so indemnify Indemnitee(s) will only apply if each of the following
                                            conditions is met:

 

		14.2.1	The
                                            Claim was not proximately caused by the Indemnitee(s)’ failure to conduct the Clinical
                                            Trial in accordance with the Protocol, other written instructions provided to the NIAID by
                                            the Company, and this Agreement;

 

		14.2.2	The
                                            Claim was not caused by the negligence, recklessness, or willful misconduct of any Indemnitee
                                            or violation of law or regulation or a material breach of this Agreement by NIAID, provided
                                            that any action properly taken by the Indemnitee in compliance with the Protocol or written
                                            instructions from the Company will be deemed, for purposes of this condition, not to be negligent,
                                            and provided further that if a Claim is jointly caused by the negligence of any Indemnitee
                                            and the administration or use of the Test Article, then Company will provide defense and
                                            indemnification solely to the extent the Claim was caused by the administration of the Test
                                            Article in accordance with the Protocol, other written instructions provided to the NIAID
                                            by the Company, and this Agreement;

 

		14.2.3	The
                                            Claim was not caused by a material alteration in or amendment to the Protocol that was not
                                            approved in writing by Company;

 

		14.2.4	The
                                            Company is promptly notified of the Claim;

 

		14.2.5	The
                                            Indemnitee(s) fully cooperates with the Company and its legal representatives in the investigation
                                            and defense of the Claim.

 

		14.3	Insurance.
                                            The Company represents and warrants that it will maintain during the term of this Agreement
                                            or the Protocol, whichever is longer, a liability insurance policy or a program of insurance
                                            or self-insurance at levels sufficient to support the indemnification obligations assumed
                                            under this Agreement and to cover the costs of medical care required to treat or stabilize
                                            adverse reactions attributable to the Test Article suffered by Human Subjects who received
                                            Test Article in accordance with the approved Protocol. Upon request, the Company will provide
                                            evidence of its insurance or self-insurance to NIAID.

 

    	 	 	Page 17 of 21

     

    

 

	NIAID Intramural Clinical Trial Agreement (Clinical Center)	NIAID Protocol # 16-I-0032
	Jasper Therapeutics NIAID	 

 

		14.4	Human
                                            Subject Injury or Illness Attributable to the Test Article. The Company will pay the
                                            reasonable cost of medical care required by Human Subjects for illness or injury attributable
                                            to the Test Article, to the extent such costs are (i) not covered by the Human Subject’s
                                            medical or hospital insurance or by third party or governmental programs providing such coverage,
                                            and (ii) not the result of the Human Subject’s pre-existing abnormal medical condition
                                            or underlying disease or the NIAID’s gross negligence. For purposes of this determination
                                            and the Company’s obligation under this Agreement, “attributable” means
                                            that the receipt of the Test Article and the Clinical Trial Human Subject’s illness
                                            or injury are reasonably related in time, and the illness or injury is more likely explained
                                            by the receipt of the Test Article than any other cause. The payment or offer of payment
                                            of any amount by the Company on behalf of a Human Subject or his or her healthcare insurer
                                            or other third party payer under this Section is not an admission of fault or liability by
                                            any one or more of (a) the Government or any agency thereof; or (b) the Company,
                                            its employees or agents, and any such payment or offer of payment will not be considered
                                            a waiver of any defense or other legal right by any of the foregoing in any legal, administrative
                                            or similar proceeding.

 

		14.5	Limitation
                                            on Liability. Each party shall be liable for such loss, claim, damage, or liability that
                                            said party incurs as a result of its activities under this Agreement, except that NIH, as
                                            an agency of the United States, assumes liability only to the extent provided under the Federal
                                            Tort Claims Act, 28 U.S.C. §§ 2671 et seq. In no event shall Company be
                                            liable to the NIAID or any party for any special incidental or consequential damages arising
                                            out of or relating to this Agreement, or the subject matter hereof, however caused and whether
                                            such claim is based in contract, tort (including negligence and strict liability) or otherwise,
                                            even if authorized representative of Company is advised of the possibility of such damages.
                                            Except for Company’s indemnification obligations hereunder, the total, cumulative
                                            liability of Company arising out of or related to this Agreement shall not exceed [...***...]
                                            U.S. dollars ($[...***...]).

 

		14.6	Disclaimer.
                                            Except as specifically stated in Section 5.6, the Test Article is provided “AS
                                            IS” and “WITH ALL FAULTS”, and the Company expressly disclaims any warranties,
                                            express or implied, of any kind, including any implied warranties of merchantability, fitness
                                            for a particular purpose or noninfringement of intellectual property rights of third parties.

 

		15.	DISPUTES

 

Any
dispute arising under this agreement that is not disposed of by Agreement of the Parties will be submitted jointly to the signatories
of this Agreement. If the signatories are unable to jointly resolve the dispute within [...***...] after notification thereof,
the dispute will be referred to the Director of NIAID (or his/her designee) and an appropriate authorized representative of the Company
for resolution. If the Director of NIAID (or his/her designee) and the authorized representative of the Company are unable to jointly
resolve the dispute within [...***...], either Party may pursue any and all administrative or judicial remedies that may be
available.

 

		16.	INDEPENDENT
                                            CONTRACTORS

 

In
the performance of all work under this Agreement, neither Party is authorized or empowered to act as agent for the other for any purpose
and will not, on behalf of the other Party, enter into any contract, warranty, or representation as to any matter. Neither Party will
be bound by the acts of the other Party.

 

    	 	 	Page 18 of 21

     

    

 

	NIAID Intramural Clinical Trial Agreement (Clinical Center)	NIAID Protocol # 16-I-0032
	Jasper Therapeutics NIAID	 

 

		17.	NON-ENDORSEMENT

 

By
entering into this Agreement, the NIAID does not directly or indirectly endorse any product or service provided, or to be provided, by
the Company. The Company will not in any way state or imply that this Agreement is an endorsement of those product(s) or service(s) by
the Government or any of its organizational units or employees. However, the Company may reference or use publications and reports based
on the Clinical Trial for legitimate business and regulatory purposes.

 

		18.	AMENDMENTS

 

Modifications
to this Agreement will not be effective unless made in writing, as mutually agreed, and signed by a duly authorized representative of
each Party.

 

		19.	SURVIVABILITY

 

The
provisions of Sections 2 (Clinical Research Site and Investigators), 3 (Investigational New Drug Application Sponsorship),
4 (FDA Meetings/Communications), 5 (Supply, Distribution, and Use of Test Article), 8 (Human Subjects Protection),
9 (Data Analysis and Management; Clinical Specimens and Isolates), 10 (Publications and Press Releases), 11 (Confidential
Information), 12 (Intellectual Property), 14 (Liability, Indemnification, Insurance, and Research Related Injury),
17 (Non-Endorsement), this Section 19 (Survivability) and sub-Section 23.4 will, in each case, survive
the expiration or earlier termination of this Agreement.

 

		20.	ENTIRE
                                            AGREEMENT AND SEVERABILITY

 

This
Agreement constitutes the entire Agreement and understanding of the Parties with respect to the subject matter hereof and supersedes
any prior understanding or written or oral Agreement. The provisions of this Agreement are severable and, in the event that any provision
of this Agreement will be determined to be invalid or unenforceable under any controlling body of law, such determination will not in
any way affect the validity and enforceability of the remaining provisions of this Agreement.

 

		21.	ASSIGNMENT

 

Neither
this Agreement nor any rights or obligations of any Party hereunder will be assigned or otherwise transferred by either Party without
the prior written permission of the other Party, provided, however, that the Company may assign this Agreement at any time without the
consent of NIAID to any Affiliate of Company or to any third party in connection with a sale of all or substantially all of the business
or assets of Company that relate to this Agreement to such third party.

 

		22.	APPLICABLE
                                            LAW

 

This
Agreement will be construed in accordance with Federal law as applied by the Federal courts of the District of Columbia.

 

		23.	TERM
                                            AND TERMINATION

 

		23.1	Unless
                                            terminated sooner in accordance with this Section 23, this Agreement will expire
                                            upon receipt of the final study report by the Company.

 

		23.2	The
                                            Parties may terminate this Agreement at any time by mutual written consent.

 

    	 	 	Page 19 of 21

     

    

 

	NIAID Intramural Clinical Trial Agreement (Clinical Center)	NIAID Protocol # 16-I-0032
	Jasper Therapeutics NIAID	 

 

		23.3	Either
                                            Party may unilaterally terminate this Agreement at any time by giving written notice at least
                                            thirty (30) calendar days prior to the desired termination date.

 

		23.4	If
                                            this Agreement is terminated prior to completion of the Protocol, the Protocol will be completed
                                            if medically or ethically appropriate. In that event, each enrolled Human Subject will be
                                            followed through the period outlined in the Protocol and the Company will use its best commercial
                                            efforts to supply enough Test Article to complete the Protocol for the maximum number of
                                            Human Subjects identified in the approved Protocol at the time of the notice of termination.

 

		23.5	In
                                            the event the Company elects to terminate its obligations under the terms of this Agreement,
                                            due to an unexpected dissolution, the Company must notify NIAID within at least thirty (30) calendar
                                            days of the dissolution; and use its best efforts to provide NIAID with the resources necessary
                                            to complete the Protocol in addition to the terms of Section 5 above.

 

		24.	NOTICES

 

Any
notice or report required under the terms of this Agreement will be sent to the other Party at the addresses indicated below. Any notice
will be deemed to be effective when delivered to the other Party by courier, registered mail (with return receipt), via facsimile, Portable
Document Format (PDF), or email followed by conformational hard copies when requested.

 

For
the Company:

 

For
legal matters: [...***...]

Jasper
Therapeutics, Inc.

2200
Bridge Parkway, Ste. 102

Redwood
City, CA 94065

[...***...]

 

For
technical/clinical matters:

[...***...]

Jasper
Therapeutics, Inc.

2200
Bridge Parkway, Ste. 102

Redwood
City, CA 94065

 

For
the NIAID:

 

For
Agreement term matters:

 

NIAID-TTIPO,
Attn. [...***...]

5601
Fishers Lane, [...***...]

Rockville,
Maryland 20852 USA

Ph:
[...***...] / Fax: [...***...]

 

For
technical/clinical matters:

 

[...***...]

 

[...***...],
NIH-NIAID-LCIM

[...***...]

10
Center Drive

Bethesda,
MD 20814

Ph:
[...***...] / Fax: [...***...]

 

SIGNATURES
BEGIN ON THE NEXT PAGE

 

    	 	 	Page 20 of 21

     

    

 

	NIAID Intramural Clinical Trial Agreement (Clinical Center)	NIAID Protocol # 16-I-0032
	Jasper Therapeutics NIAID	 

 

If
the Company agrees with the terms of this Agreement for the Clinical Trial in accordance with the Protocol designated as Protocol No.
16-1-0032 for JSP191 the title of which is “High Dose Peripheral Blood Stem Cell Transplantation
with Post Transplant Cyclophosphamide for Patients with Chronic Granulomatous Disease,” please have an authorized representative
sign below.

 

	FOR NIAID:	 	 
	 	 	 
	/s/ Karyl S. Barron -S	 	5/3/2021
	Steven M. Holland, M.D.	 	Date
	Director, Division of Intramural Research	 	 
	National Institute of Allergy and 

Infectious Diseases	 	 
	National Institutes of Health	 	 
	Department of Health and Human Services	 	 
	 	 	 
	FOR COMPANY:	 	 
	 	 	 
	/s/ Jeet Mahal	 	5/7/21
	(Signature)	 	Date
	Jeet Mahal	 	 
	Chief Financial Officer	 	 
	Jasper Therapeutics, Inc.	 	 
	2200 Bridge Parkway, Ste. 102	 	 
	Redwood City, CA 94065	 	 

 

Page 21 of 21

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}]]